Combining AI-Based Antibody Design Technology
with Global New Drug Development Expertise
On June 11, Galaxy, an artificial intelligence (AI) drug discovery company, and Hanolbiopharma, a company specializing in new drug development, announced that they have begun a strategic joint research project to develop antibody-based cancer therapeutics.
This collaboration aims to develop antibody therapeutics that must meet complex requirements through precise AI-driven design. Leveraging AI-based technology, the two companies plan to jointly develop therapeutics that maximize efficacy and minimize side effects by designing antibodies that are difficult to obtain through conventional methods.
Galaxy will utilize its protein design AI platform, "GalaxyDesign," which is trained on the physicochemical principles of protein structures. This platform is known for its ability to design entirely new antibodies from scratch and to identify precision drug molecules that are difficult to discover using traditional methods. In March, GalaxyDesign successfully used AI to design new antibodies for six novel drug targets.
Hanolbiopharma is a global biotech company specializing in the development of antibody and protein-based therapeutics. The company is developing innovative new drugs in major therapeutic areas such as autoimmune diseases, ophthalmic diseases, and cancer, leveraging its accumulated clinical experience and global pipeline. Recently, "Batoclimab," an autoimmune disease therapeutic under development, was designated as an orphan drug for thyroid eye disease in Japan, and the company has achieved positive results in a phase 3 clinical trial for myasthenia gravis, continuing its track record of success.
The two companies plan to gradually advance the discovery and validation of differentiated antibody therapeutics through this joint research. Seok Chaok, CEO of Galaxy, stated, "Galaxy's proprietary AI protein design technology can provide new solutions to the challenges faced by the drug development industry," adding, "We hope that this collaboration will fully leverage our technological strengths and lead to meaningful research outcomes."
An Hyekyung, Head of Research at Hanolbiopharma, said, "Hanol has continuously pursued innovation in drug development based on AI technology, and this collaboration is a strategic extension of that effort," adding, "We look forward to further expanding the depth and speed of our research and development through technological synergy with Galaxy."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
